{
  "name": "Canagliflozin (SGLT2 Inhibitor)",
  "category": "pharmaceutical",
  "evidenceGrade": "B",
  "riskProfile": "medium",
  "description": "SGLT2 inhibitor that blocks glucose reabsorption in kidneys, causing glycosuria (glucose excretion in urine). Extended lifespan in the NIA ITP. Beyond diabetes, shows remarkable cardio-renal protective effects and mimics aspects of caloric restriction.",
  "mechanisms": [
    "SGLT2 inhibition (renal glucose excretion)",
    "Caloric restriction mimetic (~200-300 cal/day excreted)",
    "Ketogenesis promotion",
    "Cardiovascular and renal protection"
  ],
  "dosage": {
    "standard": "100mg/day",
    "range": "100-300mg/day",
    "notes": "Prescription. ITP-positive for lifespan extension. CREDENCE and CANVAS trials. Causes glycosuria â€” keep hydrated. Monitor for UTIs."
  },
  "keyFindings": [
    "Extended lifespan in male mice in NIA ITP (genetically heterogeneous)",
    "CANVAS program: 14% reduction in cardiovascular events",
    "CREDENCE: 30% reduction in kidney disease progression"
  ],
  "interactions": [
    "Insulin and sulfonylureas (hypoglycemia risk)",
    "Diuretics (volume depletion)",
    "Loop diuretics"
  ],
  "sideEffects": [
    "Genital mycotic infections (yeast)",
    "UTIs",
    "Polyuria",
    "Hypotension",
    "DKA (rare)"
  ],
  "contraindications": [
    "Severe renal impairment (eGFR <30)",
    "Type 1 diabetes",
    "Recurrent UTIs or genital infections"
  ],
  "tags": [
    "pharmaceutical",
    "sglt2",
    "itp-positive",
    "longevity-drug",
    "cardiovascular",
    "renal",
    "prescription"
  ],
  "estimatedMonthlyCost": {
    "low": 15,
    "mid": 40,
    "high": 100,
    "currency": "USD"
  },
  "id": "prod-canagliflozin-sglt2-inhibitor",
  "sources": [],
  "suppliers": [],
  "communityReports": [],
  "expertOpinions": [],
  "lastUpdated": "2026-02-04T14:50:14.815Z",
  "createdAt": "2026-02-04T14:50:14.815Z"
}